The new and the old that is new again

被引:3
|
作者
Graff, Julie N. [1 ]
Beer, Tomasz M. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Knight Canc Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA
关键词
RESISTANT PROSTATE-CANCER; ORTERONEL TAK-700; PLUS PREDNISONE; DOUBLE-BLIND; CHEMOTHERAPY; ENZALUTAMIDE; MULTICENTER; THERAPY; TRIAL;
D O I
10.1038/nrclinonc.2015.226
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 2015, published trials highlighted the remarkable efficacy of docetaxel combined with androgen-deprivation therapy in patients with newly diagnosed metastatic prostate cancer. Also in 2015, a large study revealing potential molecular targets for metastatic castration-resistant prostate cancer therapies was published, along with a study showing activity of PARP inhibition in patients harbouring mutations in genes governing DNA repair.
引用
收藏
页码:73 / 74
页数:2
相关论文
共 50 条